Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1204 W Main St
Charlottesville, VA 22903Phone+1 434-924-0123Fax+1 434-243-3300
Education & Training
- National Cancer InstituteFellowship, Pediatric Hematology/Oncology, 2008 - 2012
- Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2008 - 2011
- University of Texas Health Science Center at HoustonResidency, Pediatrics, 2005 - 2008
- University of Texas M.D. Anderson Cancer CenterPost-Doctoral Fellowship, 2003 - 2005
- McGovern Medical School at UTHealthClass of 2003, MD
Certifications & Licensure
- VA State Medical License 2016 - 2026
- MD State Medical License 2008 - 2016
- TX State Medical License Active through 2012
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma Start of enrollment: 2012 Jun 29
- Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Start of enrollment: 2014 Nov 01
- Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Start of enrollment: 2016 Feb 01
Publications & Presentations
PubMed
- 66 citationsCD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.Haneen Shalabi, Haiying Qin, Angela Su, Bonnie Yates, Pamela L Wolters
Blood. 2022-08-04 - 100 citationsAutologous lymphapheresis for the production of chimeric antigen receptor T cellsElizabeth S. Allen, David F. Stroncek, Jiaqiang Ren, Anne F. Eder, Kamille A. West
Transfusion. 2017-05-01 - 887 citationsCD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Terry J. Fry, Nirali N. Shah, Rimas J. Orentas, Maryalice Stetler-Stevenson, Constance M. Yuan
Nature Medicine. 2018-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: